Ad Header

PharmaLive

Slogan

The Pulse of the Pharmaceutical Industry

  • Filter By Category

  • Filter By Author

GSK to Acquire Celiac-Focused Sitari Pharmaceuticals

GlaxoSmithKline will acquire San Diego-based Sitari Pharmaceuticals and the company’s transglutaminase 2 small molecule program for celiac disease.

Read More »

FTC tells cannabis companies not to advertise disease treatments without science

The Federal Trade Commission warned three companies selling products infused with cannabidiol that it was illegal to advertise that such products could fight disease without providing credible scientific evidence.

Read More »

AstraZeneca Bolsters Machine Learning for Drug Development with Schrödinger Deal

AstraZeneca struck a deal to use Schrödinger’s advanced computing platform to help accelerate drug discovery efforts.

Read More »

CureVac and Yale Team Up for mRNA-Based Lung Therapies

Tubingen, Germany-based CureVac entered a collaboration research agreement with Yale University to focus on lung therapies.

Read More »

Jazz Pharmaceuticals Announces Acquisition of Cavion

Jazz Pharmaceuticals plc announced the acquisition of clinical-stage biotechnology company Cavion Inc. through a merger with a Jazz subsidiary.

Read More »

European panel clears GW Pharma cannabis drug

GW Pharmaceuticals’ marijuana-based treatment Epidyolex won a positive recommendation for marketing approval from a European Medicines Agency (EMA) panel for use as an additional treatment for two types of seizures.

Read More »

Genentech Strikes Three Drug Discovery Deals

In a deal-making morning for South San Francisco-based Genentech, the Roche subsidiary struck three separate transactions with small companies to boost drug development.

Read More »

Top 10 Pipelines To Watch: 2019 Annual Report

The return on R&D investment for leading biopharmaceutical manufacturers fell to a nine-year low while the U.S. FDA approved a record-breaking amount of novel medicines during 2018.

Read More »

IFM Therapeutics Launches New Subsidiary Aimed at Parkinson’s and NASH

IFM Therapeutics launched a second subsidiary in less than a year. The Boston-based company launched IFM Due, a subsidiary company developing a suite of cGAS inhibitors and STING antagonists that can target diseases such as NASH, lupus and Parkinson’s.

Read More »

AI Gaining Ground in Drug Development

Machine learning and artificial intelligence (AI) may resoundingly improve on traditional methods of drug development by biopharmaceutical companies.

Read More »

Ad Right Top

MedAdNews

Extensive pharmaceutical business and marketing intelligence. For back issues, please contact MDAD@kmpsgroup.com.

August 2019 Focus: AI, AR/VR, Top 200 Medicines, Lions Health Takeaways, and more!

Subscribe

Ad Right Bottom